rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Organogenesis Holdings Inc. - Class A

ORGO · Nasdaq

Health CareBiotechnologyNot moving yet

ORGO stood above a rising 150-day average in 8 of the last 52 weekly readings, and has been out of that trend for the last 41 weeks. It is 53.3% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 41
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$80K
Insider sales, 12 months
$2.6M
Officials’ trades on record
0
Institutions holding
128 (+15)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 8 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.5M$0$1.0MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months4
Buyers · sellers2 · 1
WhoDidSharesTraded
Michael Joseph DriscollDirectorbought10,000at $2.679 Mar 2026filed 11 Mar 2026
Arthur S. LeibowitzDirectorbought5,000at $2.689 Mar 2026filed 11 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders128+15 on the quarter
New · exited31 · 17
Reported value$156.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
MORGAN STANLEYadded · filed 13 Aug 202611,721,609$28.5M+104,814+0.9%
Soleus Capital Management, L.P.added · filed 11 Aug 202610,140,951$24.6M+55,000+0.5%
BlackRock, Inc.added · filed 7 Aug 20267,249,528$17.6M+2,349,777+48.0%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20263,050,297$7.4M+159,291+5.5%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 20263,011,753$7.3M+2,130,036+241.6%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,905,919$7.1M+5,103+0.2%
D. E. Shaw & Co., Inc.added · filed 14 Aug 20262,888,313$7.0M+590,339+25.7%
Assenagon Asset Management S.A.unchanged · filed 8 Jul 20261,967,952$4.8M00.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,935,554$4.7M+151,590+8.5%
DEUTSCHE BANK AG\added · filed 7 Aug 20261,706,186$4.1M+5050.0%
31 Mar 2023 – 30 Jun 2026
86111135Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Arthur S. Leibowitz Company insiderDirector · last 9 Mar 20264 · 0
Michael Joseph Driscoll Company insiderDirector · last 9 Mar 20262 · 1
Robert Cavorsi Company insiderVice President, Strategy · last 1 Mar 20260 · 0
Antonio S. Montecalvo Company insiderVice President, Health Policy · last 18 Feb 20260 · 2
Brian Grow Company insiderChief Commercial Officer · last 18 Feb 20260 · 0
David Francisco Company insiderChief Financial Officer · last 18 Feb 20260 · 0
Garrett Lustig Company insiderDirector · last 18 Feb 20260 · 0
Gary S. Gillheeney Company insiderPresident and CEO · last 18 Feb 20260 · 29
Gilberto Quintero Company insiderDirector · last 18 Feb 20260 · 0
Jon L. Giacomin Company insiderDirector · last 18 Feb 20260 · 0
Lori Freedman Company insiderChief Admin. and Legal Officer · last 18 Feb 20263 · 0
Michele Ilene Korfin Company insiderDirector · last 18 Feb 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 20257.9%
Free cash flow marginFY 2025 · to 31 Dec 2025-4.3%
Return on capital employedFY 2025 · to 31 Dec 20259.0%
Cash conversionFY 2025 · to 31 Dec 2025-27.8%
Research spendFY 2025 · to 31 Dec 20257.9%
Share count trendFY 2025 · to 23 Feb 20261.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$93.7M
Free cash flowFY 2025 · to 31 Dec 2025−$24.5M

Analyst forecasts

No analyst forecasts yet.